Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Capvaxive by Year
Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — Worldwide sales ($M) ($M)
Merck Capvaxive: $759M in FY2025, up 682.5% from a year earlier.
Where the FY2025 figure comes from
“|| Capvaxive | 142 | 184 | 325 | 107 | 129 | 236 | 244 | 279 | 759 | 42 | 40 | 38 | 36”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Capvaxive (21-valent adult pneumococcal conjugate vaccine, launched Q2 2024) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 759 | +682.5% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 97 | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2026-02-24) ↗ |
Breakdown
What makes up capvaxive
Cite this data
StockData. (2026). Merck Capvaxive ($M), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-capvaxive
See every metric in the Merck KPI table. Data updated Oct 26, 2026.